BAY-1797 is a highly potent, orally bioavailable, and specific P2X4 antagonist with an IC50 of 211 nM against human P2X4. BAY-1797 displays no or very weak activity on the other P2X ion channels. BAY-1797 shows anti-nociceptive and anti-inflammatory effects. The
anti-inflammatory and anti-nociceptive effects of BAY-1797 were
demonstrated in a mouse complete Freund's adjuvant (CFA) inflammatory
pain model.